From Surf Wiki (app.surf) — the open knowledge base

DOTFM

Psychedelic drug

| elimination_half-life =

(hydrochloride)

2,5-Dimethoxy-4-trifluoromethylamphetamine (DOTFM) is a psychedelic drug of the phenethylamine, amphetamine, and DOx families. It is the α-methylated analogue of 2C-TFM. The drug is the most potent DOx psychedelic.

Use and effects

According to Daniel Trachsel, DOTFM is active as a psychedelic in humans at doses of 0.3 to 1mg (300–1,000μg) and its duration is not listed. It is the most potent psychedelic of the DOx family, followed by DOB (dose range 1–3mg).

Interactions

Pharmacology

Pharmacodynamics

DOTFM acts as an agonist at the serotonin 5-HT2A and 5-HT2C receptors. In drug discrimination tests in rats, DOTFM fully substituted for LSD and was slightly more potent than DOI. In addition, (R)-DOTFM robustly induces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, with equivalent potency as (R)-DOI. The drug is around twice as potent as 2C-TFM in animal studies.

In contrast to (R)-DOI, which has extraordinarily potent serotonin 5-HT2A receptor-mediated anti-inflammatory effects, DOTFM shows no anti-inflammatory effects. The differences between the drugs in this regard appear to be due to differences in functional selectivity at the serotonin 5-HT2A receptor.

History

DOTFM was first synthesized in 1994 by a team at Purdue University led by David E. Nichols. The threshold dose in humans was reported by Alexander Shulgin in his 2011 book The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds, who cited personal communication with an anonymous individual in 2003 as the source for the information. Subsequently, Daniel Trachsel described a wider dose range in 2013, although did not report its duration.

Society and culture

Legal status

Canada

DOTFM is a controlled substance in Canada under phenethylamine blanket-ban language.

References

(2012). "Fluorine in psychedelic phenethylamines". Drug Test Anal.
(2013). "Phenethylamine: von der Struktur zur Funktion". Nachtschatten-Verlag.
(February 2017). "Psychedelics as Medicines: An Emerging New Paradigm". Clinical Pharmacology and Therapeutics.
(November 2008). "Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency". The Journal of Pharmacology and Experimental Therapeutics.
(2022). "Differential Regulation of Inflammatory Responses Following 5-HT 2 Receptor Activation in Pulmonary Tissues". The FASEB Journal.
(February 2024). "Serotonin-2 Receptor Agonists Produce Anti-inflammatory Effects through Functionally Selective Mechanisms That Involve the Suppression of Disease-Induced Arginase 1 Expression". ACS Pharmacology & Translational Science.
(December 1994). "1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist". Journal of Medicinal Chemistry.
(2011). "[[The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds]]". [[Transform Press]].
"Controlled Drugs and Substances Act".

Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

5-ht2a-agonists 5-ht2c-agonists daniel-trachsel david-e.-nichols dox-(psychedelics) psychedelic-phenethylamines substances-discovered-in-the-1990s trifluoromethyl-compounds

Want to explore this topic further?

Ask Mako anything about DOTFM — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report